Purespring Therapeutics to Present Gene Therapy Research at ASN Kidney Week 2025
Purespring Therapeutics, a biotechnology company developing genetic therapies for kidney diseases, will present three scientific posters at the American Society of Nephrology (ASN) Kidney Week 2025, taking place November 5–9 in Houston, Texas. The presentations will focus on the company’s investigational gene therapy PS-002 and associated research efforts in nephrology.
The first poster outlines the design of Purespring’s Phase I/II clinical trial of PS-002, an adeno-associated virus (AAV)-based gene therapy intended to deliver the complement factor I (CFI) gene to podocytes in patients with IgA nephropathy (IgAN). This strategy aims to modulate complement activation locally within the glomerulus without affecting systemic complement activity. A single administration of PS-002 is intended to enable long-term expression of CFI in non-dividing podocytes. The study will be presented by Dr. Fredrik Erlandsson, Chief Medical Officer, on November 7.
A second poster, to be presented on November 8, summarizes findings from patient and caregiver insight sessions conducted by the IgA Nephropathy Foundation and the UK’s National Institute for Health and Care Research. Participants from the U.S. and UK provided feedback on the concept of gene therapy for renal conditions, including preferences related to trial design and treatment characteristics. According to the abstract, there was a high level of interest in the potential for single-dose therapies.
The third presentation, led by researchers from the University of Bristol and co-authored by Purespring collaborators, examines NPHS2 pathogenic variants using data from over 1.2 million genomes. The analysis estimates genotype frequencies in the U.S., UK, Europe, and Japan and evaluates correlations with disease onset and progression in focal segmental glomerulosclerosis (FSGS) and steroid-resistant nephrotic syndrome (SRNS). The data suggest regional differences in the age of disease onset, with adult-onset cases more common in the U.S. and childhood-onset cases more frequently observed in Europe and East Asia. This poster will be presented on November 6.
In recent months, Purespring received regulatory approvals to initiate its Phase I/II trial of PS-002 in patients with IgAN. The company was granted Investigational New Drug (IND) clearance by the U.S. Food and Drug Administration in July 2025 and Clinical Trial Authorisation by the UK’s Medicines and Healthcare products Regulatory Agency in August 2025.